Overview
Fragile X syndrome is the most common inherited cause of cognitive impairment (~1 in 7,000 males, 1 in 11,000 females). Diagnosis is made with a single laboratory test, and it sheds light on a wide area, from the child's educational plan to the health follow-up of relatives on the maternal side.
Genetic Cause — The Language of Repeats
The length of the CGG sequence at the start of the FMR1 gene determines the picture:
- Normal: ~5-44 repeats
- Premutation (55-200): Carriers do not show the syndrome but carry two separate risks: premature ovarian insufficiency (FXPOI) in women, and FXTAS (tremor-ataxia disorder) in both sexes at older ages. The repeats can lengthen as they pass from mother to child.
- Full mutation (>200): The gene is "locked" by methylation, and the FMRP protein cannot be produced → Fragile X syndrome. FMRP is the brake on protein production at synapses; in its absence, connections cannot mature.
Girls are generally less severely affected, owing to their second (intact) X chromosome.
Clinical Profile
Early childhood
- Speech delay (often the first presenting complaint), hypotonia, sensory sensitivity (sound/touch), avoidance of eye contact
- Autism spectrum features (30-50%), hand flapping, hand biting; however, social interest is largely preserved inwardly (a "shy autism" appearance)
- Overactivity and attention problems are almost the rule
Physical findings
- Long face, prominent ears (becoming more noticeable with age), macro-orchidism at puberty
- Connective tissue laxity: joint laxity, flat feet, recurrent middle ear infections, mitral valve prolapse (monitor for a murmur in adulthood)
- Seizures in ~10-15% (usually well controlled and resolving by adolescence)
Diagnosis — and the Family Map
- The test is straightforward: FMR1 CGG repeat analysis; it is part of the standard panel for any developmental delay/autism of unexplained cause
- A positive diagnosis initiates a cascading family screening: the mother is a definite carrier → aunts and the maternal grandparents' line should be tested; women with the premutation should be given counselling on FXPOI (family planning!) and FXTAS at older age — a single diagnosis concerns three generations
Treatment and Follow-up
The core: educational-behavioural support
- Early intensive speech-language therapy; a learning environment supported with visual aids and routine; sensory regulation strategies (occupational therapy)
- Advance notice of transitions and managing crowds/noise reduce behavioural outbursts
Medications (symptom-targeted)
- ADHD: Stimulants can be effective; started at a low dose at a young age because of the risk of restlessness as an adverse effect
- Anxiety/irritability: SSRIs are frequently used; in severe irritability, a low-dose atypical antipsychotic (with weight-metabolic monitoring)
- Sleep: Melatonin plus sleep hygiene
- If seizures occur, they generally respond well to standard treatment
Follow-up checklist
- Hearing (serous otitis), vision (strabismus), joint-foot assessment, cardiac auscultation (MVP) in adolescence/adulthood, dental-jaw follow-up
Prognosis — An Honest Framework for Families
- Life expectancy is normal.
- Cognitive level: Boys mostly have moderate learning difficulty; a significant proportion of girls remain close to the normal range. Speech is delayed but mostly develops.
- Behaviour: Anxiety and attention problems can become more difficult in adolescence, and often ease in adulthood; in a structured environment, many individuals can work in supported jobs and achieve partial independence.
- Seizures generally remain confined to childhood.
- Knowledge of FXPOI/FXTAS on the family side allows "foresight" for future generations.
Research Horizon and Treatment Pipeline
- Zatolmilast (a PDE4D inhibitor): The primary cognitive endpoint was not met in two phase 3 trials (May 2026) — an important but not direction-changing lesson for the field: the first generation of targeted trials has not come to an end, and the measurement methods are also being questioned.
- Candidates such as transdermal cannabidiol and metformin continue to be investigated in small-to-medium scale studies with mixed results.
- Long term — unlocking the gene: Since the gene itself is intact, the most logical target is to remove the silencing marks at the CGG region and reactivate FMR1; CRISPR/epigenetic editing approaches are working in the laboratory, awaiting the solution of the delivery problem for translation to humans.
Current stage table: Genetic Treatments — Fragile X treatment pipeline.
Daily Life and Supports
- At school: a predictable routine, visual schedules, sensory breaks, written instructions
- An "exit plan" in the community against sudden stimulus-triggered outbursts (a quiet corner, headphones)
- Carrier counselling for siblings and the extended family should not be postponed
- Joining patient associations; sharing behavioural data (sleep/tantrum diary) at check-ups
Downloadable Documents: Emergency Action Plan + Routine Follow-up Calendar (PDF)
Two documents have been prepared for children with Fragile X by Nörogender, under the guidance of Prof. Dr. Burak Tatlı. The Emergency Action Plan (3 pages): contains fillable identity/medication fields, what to do during a seizure and the 5-minute rule, as well as two warnings specific to Fragile X — that a behavioural crisis triggered by sensory overload is not a seizure, and emergency department environment adaptation (a calm, dim area, family present, short sentences) — along with the information that seizures usually follow a benign course and there is no syndrome-specific medication restriction. The Routine Follow-up Calendar (2 pages): what needs to be done at the time of diagnosis (including family cascade testing and FXPOI/FXTAS counselling), a year-by-year follow-up table from 0-3 years of age to adulthood, and a record chart to be filled in at check-ups.
📄 Emergency Action Plan (PDF, 3 pages) — in Turkish 📅 Routine Follow-up Calendar (PDF, 2 pages) — in Turkish
Complete the documents together with your doctor; keep a copy at home and at school.
